Johnson & Johnson (J&J) has closed the previously announced acquisition of Abiomed, a medical device technology company, for an enterprise value of around $16.6bn, in a move to strengthen its MedTech portfolio. The acquisition of Abiomed, which was announced in November 2022, is expected to add heart recovery solutions to the MedTech portfolio of Johnson […]
The US Food and Drug Administration (FDA) has cleared Abiomed to use the company’s version of Impella ECP pivotal heart pump in pivotal clinical trial. The Impella ECP pivotal clinical trial is a single-arm, prospective, and multi-center trial and has enrolled the first two patients. The clinical trial will assess the rate of major adverse […]
Johnson & Johnson (J&J) has agreed to acquire Abiomed, a NASDAQ-listed cardiovascular medical technology provider, in an all-cash deal valued at approximately $16.6 billion. The proposed acquisition is expected to further diversify and expand Johnson & Johnson MedTech (JJMT) portfolio into the heart failure and recovery segment through Abiomed’s Impella heart pump platform. Joaquin Duato […]